Ludivine Grzelak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3017148/publications.pdf Version: 2024-02-01



LUDIVINE COZELAK

#	Article	IF	CITATIONS
1	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Medicine, 2021, 27, 917-924.	30.7	617
2	A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations. Science Translational Medicine, 2020, 12, .	12.4	228
3	Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nature Immunology, 2019, 20, 613-625.	14.5	180
4	SARSâ€CoVâ€2 Alpha, Beta, and Delta variants display enhanced Spikeâ€mediated syncytia formation. EMBO Journal, 2021, 40, e108944.	7.8	139
5	Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nature Immunology, 2021, 22, 1428-1439.	14.5	110
6	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine, 2020, 59, 102915.	6.1	101
7	SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. Eurosurveillance, 2021, 26, .	7.0	69
8	Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2021, 224, 983-988.	4.0	65
9	Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. Cell Reports Medicine, 2021, 2, 100275.	6.5	64
10	Single-Cell Approach to Influenza-Specific CD8+ T Cell Receptor Repertoires Across Different Age Groups, Tissues, and Following Influenza Virus Infection. Frontiers in Immunology, 2018, 9, 1453.	4.8	63
11	A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis. Med, 2021, 2, 1072-1092.e7.	4.4	38
12	Human Mucosal-Associated Invariant T Cells in Older Individuals Display Expanded TCRαβ Clonotypes with Potent Antimicrobial Responses. Journal of Immunology, 2020, 204, 1119-1133.	0.8	36
13	Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. Journal of Experimental Medicine, 2022, 219, .	8.5	34
14	Type I interferon response and vascular alteration in chilblainâ€like lesions during the COVIDâ€19 outbreak*. British Journal of Dermatology, 2021, 185, 1176-1185.	1.5	33
15	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Science Advances, 2021, 7, .	10.3	27
16	Antiâ€ <scp>HIV</scp> â€1 antibodies trigger nonâ€lytic complement deposition on infected cells. EMBO Reports, 2020, 21, e49351.	4.5	26
17	Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. EBioMedicine, 2021, 73, 103637.	6.1	19
18	Characteristics Associated with Olfactory and Taste Disorders in COVID-19. Neuroepidemiology, 2021, 55, 381-386.	2.3	6

#	Article	IF	CITATIONS
19	Analysis of Tâ€cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in patients with chilblainâ€like lesions during the COVIDâ€19 pandemic. British Journal of Dermatology, 2021, 185, 1242-1244.	1.5	5
20	Dual TCR-α Expression on Mucosal-Associated Invariant T Cells as a Potential Confounder of TCR Interpretation. Journal of Immunology, 2022, 208, 1389-1395.	0.8	2